CAPTAIN trial
-
.Profound Medical to Unveil AI-Driven BPH Module and New TULSA-PRO® Clinical Data at RSNA and SUO Meetings
words.Profound Medical (NASDAQ:PROF) will debut its AI‑enhanced TULSA‑AI Volume Reduction module for benign prostatic hyperplasia at the RSNA meeting (Nov 30–Dec 4, 2025) and present updated TULSA‑PRO data at RSNA and SUO. The add‑on automates treatment planning and temperature monitoring, cutting case time to allow multiple same‑day BPH procedures on existing hardware and billing pathways. Pilot and the CAPTAIN peri‑operative trial claim lower blood loss, shorter stays, less pain, and faster recovery versus robotic prostatectomy. Profound projects an addressable market of roughly 600,000 prostate‑disease patients annually.
